financetom
Business
financetom
/
Business
/
Market Chatter: Pfizer Plans to Sell About 540 Million Haleon Shares
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Pfizer Plans to Sell About 540 Million Haleon Shares
Oct 2, 2024 11:40 PM

12:23 PM EDT, 09/30/2024 (MT Newswires) -- Pfizer ( PFE ) intends to sell about 540 million shares in Haleon ( HLN ), Bloomberg reported, citing a statement.

Upon completion of the sale, Pfizer's ( PFE ) interest in Haleon ( HLN ) will fall to around 16.2% from about 22.6%, according to the report.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 28.87, Change: -0.22, Percent Change: -0.76

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Atlassian Insider Sold Shares Worth $1,247,202, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,247,202, According to a Recent SEC Filing
Aug 24, 2024
04:47 PM EDT, 08/22/2024 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, Co-CEO, Co-Founder, on August 21, 2024, sold 7,948 shares in Atlassian ( TEAM ) for $1,247,202. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 214,596 shares of the company, with 214,596 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024006465/xslF345X05/primarydocument.xml Price: 155.00, Change: -0.87, Percent...
Jazz Pharmaceuticals Epilepsies Drug Study Misses Primary Efficacy Goal
Jazz Pharmaceuticals Epilepsies Drug Study Misses Primary Efficacy Goal
Aug 24, 2024
04:48 PM EDT, 08/22/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Thursday a phase 3 trial in Japan of a cannabidiol oral solution for treatment-resistant epilepsies didn't meet the primary efficacy objective. The trial did not meet the primary efficacy endpoint of a pre-specified percentage change in indication-associated seizure frequency during the treatment period (up to 16 weeks)...
Onex Fund to Acquire a Majority Stake in German Manufacturer Fischbach KG
Onex Fund to Acquire a Majority Stake in German Manufacturer Fischbach KG
Aug 24, 2024
04:51 PM EDT, 08/22/2024 (MT Newswires) -- Onex ( ONEXF ) on Thursday said its Onex Partners Opportunities Fund is taking a majority stake in German manufacturer Fischbach KG for an undisclosed price. The private equity company said Fischbach is the world's largest provider of cartridge packaging solutions for sealants and adhesives used in building repair, renovation, & construction, aftermarket...
Procter & Gamble Insider Sold Shares Worth $1,797,613, According to a Recent SEC Filing
Procter & Gamble Insider Sold Shares Worth $1,797,613, According to a Recent SEC Filing
Aug 24, 2024
05:01 PM EDT, 08/22/2024 (MT Newswires) -- Shailesh Jejurikar, Chief Operating Officer, on August 20, 2024, sold 10,623 shares in Procter & Gamble ( PG ) for $1,797,613. Following the Form 4 filing with the SEC, Jejurikar has control over a total of 64,398 shares of the company, with 23,890 shares held directly and 40,508 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/80424/000112760224022801/xslF345X05/form4.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved